New evidence shows that dynamic contrast-enhanced MRI and conventional x-ray mammography play complementary roles in screening women who are genetically susceptible to breast cancer.
New evidence shows that dynamic contrast-enhanced MRI and conventional x-ray mammography play complementary roles in screening women who are genetically susceptible to breast cancer.
Results from an initial screening and at least one year of follow-up tests on 649 genetically at-risk women indicate that MRI is more sensitive than x-ray mammography, particularly with BRCA1 mutation carriers. MRI is less sensitive, however, for women with a BRCA2 mutation or family history of breast or ovarian cancer. Performing mammography with MRI improves cancer detection.
Dr. Martin Leach, a professor of physics as applied to medicine at Royal Marsden Hospital in Sutton, U.K., announced the most recent findings from the multicenter Magnetic Resonance Imaging for Breast Screening (MARIBS) Trial at the International Society for Magnetic Resonance in Medicine meeting in Seattle on Tuesday.
The genetic propensity of some women to develop breast cancer may outweigh the otherwise high cost of MRI breast screening. Two percent of breast cancers are related to BRCA1 and BRCA2 mutations, and between 45% and 55% of the affected women develop cancer by age 70. Their annual risk of breast cancer development between ages 35 and 50 is at least 20 times higher than that of the general female population in that age group, Leach said.
The MARIBS protocol involved annual MRI and mammography and blinded double readings, with at least one additional annual screening when positive findings were not found. The women's genetic status was established before testing and confirmed following positive findings. Testing was performed at 22 sites in the U.K.
Thirteen breast cancers were diagnosed among women with a BRCA1 mutation, 12 were found among women with the BRCA2 gene, and 10 were identified in subjects who tested negative for both mutations but had a family history of breast and ovarian cancer.
For BRCA1 subjects, dynamic CE-MRI was 92% sensitive to the presence of breast cancer compared with 23% for x-ray mammography. The combined tests were 92% sensitive, indicating that x-ray mammography added nothing to the sensitivity of the screening exam.
MRI screening was less potent for BRCA2 carriers at 58% sensitivity, while x-ray mammography had a sensitivity of 50%. Dynamic CE-MRI and conventional mammography combined, however, were 92% sensitive to breast cancer.
For women with a family history of breast cancer, the sensitivity rates for dynamic CE-MRI and x-ray mammography were 80% and 50%, respectively. Performed together, they were 100% sensitive to disease.
"These results indicate that we are detecting different types of breast cancers with the two techniques," Leach said.
BRCA1 and BRCA2 carriers mainly developed high-grade cancers, while the family history subjects had a more varied distribution of cancer grades. More ductal carcinoma in situ was seen among BRCA2 subjects than with the BRCA1 group. The BRCA1 group tended to be lymph node-negative and receptor-negative for estrogen and progesterone. Cancers arising among BRCA2 carriers, however, tended toward more lymph node involvement and were more often positive for estrogen and progesterone receptors. In the family history group, proportionally fewer positive nodes and more uniform distribution of receptor status were observed.
The MARIBS study concurs with three large clinical trials that have recently established that MRI is 70% to 77% sensitive to breast cancer for at-risk women, much higher than the 40% sensitivity range of conventional mammography.
"If we can build on this information in consultation with other study investigators, we will get clearer guidelines as to the relative importance of difference screening techniques in these different groups," Leach said.
CAD for breast MRI takes aim at lesion classification
Dynamic contrast-enhanced MR imaging finally comes of age
Breast-specific gamma imaging hunts for cancers
Breast MR boosts detection of ductal carcinoma in situ
Study scores breast cancer imaging techniques for high-risk women
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
July 22nd 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.